Related Experiment Video
Updated: Jan 30, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Spanish multidisciplinary clinical practice guidelines for Anderson-Fabry Disease in Adults. I. Method and
E J Calderón Sandubete1, E Briones Pérez de la Blanca2, C Alonso-Ortiz Del Río3
1Servicio de Medicina Interna, Hospital Universitario Virgen del Rocío, Sevilla, España; Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Sevilla, España; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), España; Departamento de Medicina, Universidad de Sevilla, Sevilla, España.
Insights
Anderson-Fabry disease, a genetic condition, presents diagnostic and management challenges. This study developed 92 evidence-based recommendations to guide healthcare professionals in managing Fabry disease patients.
Area of Science:
- Genetics
- Internal Medicine
- Clinical Practice Guidelines
Background:
- Anderson-Fabry disease is a severe, progressive, multisystem genetic disorder impacting life expectancy and quality of life.
- Clinical expression variability, diagnostic challenges, and treatment options necessitate evidence-based guidelines for effective patient management.
Purpose of the Study:
- To develop comprehensive, evidence-based clinical practice guidelines for managing Anderson-Fabry disease.
- To assist healthcare professionals in making informed decisions for patient care.
Main Methods:
- Systematic literature search across major databases addressing 32 clinical questions.
- Evidence synthesis and quality assessment using the GRADE methodology.
- Structured 2-round Delphi-RAND consensus process with an expert panel.
Main Results:
- Development of 92 specific recommendations for Anderson-Fabry disease management.
- Consideration of evidence quality, risk-benefit balance, patient values, equity, and resource use.
Conclusions:
- The guidelines provide a robust framework for managing Anderson-Fabry disease.
- Evidence-based recommendations aim to improve patient outcomes and quality of life.
Abstract:
Anderson-Fabry disease is a severe progressive multisystem condition of genetic origin that affects men and women, reducing their life expectancy and quality of life. The considerable variability in its clinical expression, the difficulties in diagnosing the condition and the current availability of several alternatives for its treatment represent a considerable challenge that justifies the development of evidence-based clinical practice guidelines that can help health professionals in the decision-making process for managing these patients. To develop these guidelines, we conducted a systematic search of the main reference databases using strategies adapted to each of the 32 clinical questions considered. We prepared documents to synthesise the evidence and assess its quality for each of the questions. The methodology employed is based on the Spanish methodology manual for preparing clinical practice guidelines, incorporating the GRADE methodology in the assessment of the scientific evidence and the preparation of the recommendations, considering the quality of the evidence, the risk-benefit balance, patient values and preferences, equity and use of resources. For the definitive preparation of the recommendations, we conducted a structured consensus process based on the Delphi-RAND methodology in 2 rounds, with an expert panel proposed by various scientific societies, research centres and patient associations. Ultimately, we developed 92 specific recommendations for managing Fabry disease.
Related Concept Videos
The Anderson-Darling Test
Chronic Kidney Disease II: Clinical Manifestations
Coronary Artery Disease III: Clinical Manifestations
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

